Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-677-1 | CAS number: 14634-93-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There is no reliable information available.
In an subchronic/chronic study with insufficient reported methodology and results (original paper in Russian language, Yalkut, 1971) 10 rats each (no information of strain and sex) received zinc ethylphenyl dithiocarbamate by gavage 6 times weekly in doses of 500 mg/kg bw for 1.5 months, 100 or 10 mg/kg bw for 4 months and 1 mg/kg bw for 10 months.
After a subchronic oral administration of 500 mg/kg bw of zinc ethylphenyldithiocarbamate to rats for 1.5 months some cases of deaths occurred. A dosage of 100 mg/kg bw or 10 mg/kg bw changes in the haemogram, the prothrombin time, and the cytochrome oxidase were observed. Histopathological effects on the liver, lung and kidneys were detected. The oral administration of 1 mg/kg bw over 10 months revealed no effects.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Methodology and results insufficient reported
- Principles of method if other than guideline:
- For the evaluation of the subchronic/chronic toxicity of zinc ethylphenylthiocarbamate 10 rats each (no information of strain and sex) received by gavage 6 times weekly 500 mg/kg bw for 1.5 months, 100 or 10 mg/kg bw for 4 months and 1 mg/kg bw for 10 months.
- GLP compliance:
- no
- Limit test:
- no
- Specific details on test material used for the study:
- No data
- Species:
- rat
- Strain:
- not specified
- Details on species / strain selection:
- No data
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- No data
- Route of administration:
- oral: gavage
- Details on route of administration:
- No data
- Vehicle:
- not specified
- Details on oral exposure:
- No data
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data
- Duration of treatment / exposure:
- 1.5, 4 or 10 month
- Frequency of treatment:
- 6 times weekly
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- 1.5 month
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- 4 month
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Remarks:
- 4 month
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Remarks:
- 10 month
- No. of animals per sex per dose:
- 10 rats/dose
- Control animals:
- not specified
- Details on study design:
- Mortality, body weight, clinical biochemistry and haematological finding and histopathological examination.
- Observations and examinations performed and frequency:
- Mortality, body weight, clinical biochemistry and haematological finding and histopathological examination.
- Sacrifice and pathology:
- AHistopathological results were reported.
- Clinical signs:
- not specified
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- At a dosage of 500 mg/kg bw 3 rats died after 32, 34 or 41 days. The other dosages did not cause any deaths.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At a dose of 500 mg/kg bw the body weight gain was 12% (after 1.5 months) lowever than in the control group, at a dosage of 100 mg/kg bw the body weight gain was 16% (after 2 months) lower than in the control group.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In the haemogram the both upper dosages caused "strong disorders". With a dosage of 10 mg/kg bw at the end of the thrird months there was a trend towards a reduced erythrocyte number and at the end of the experiment a strong
reticulocytosis was seen. Furthermore, the prothrombin time was decreased after 3 months (administration of 100 mg/kg bw) or 4 months (administration of 10 mg/kg bw). - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The cytochrome oxidase activity in the liver was decreased after 4 months (100 mg/kg bw), the ceruloplasmin activity was decreased 4 months after administration of 100 mg/kg bw and 3 months after administration of 10 mg/kg bw.
Furthermore, after the administration of 100 mg/kg bw an increase in the catalase index (p <0.05) was observed.. - Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Slight granular degeneration of liver cells, increased aveolar and histocytic cells in the lungs, peribronchial infiltration, dilatation and hyperemia of the renal vessels, granular degenerationof the tubular epithelium with isolated necroses as well as dilated spleen vessels were observed at a dosage of 100 mg/kg bw and 10 mg/kg bw. At a dosage of 100 mg/kg bw numerous megakaryocytes were found in the spleen pulp.
- Histopathological findings: neoplastic:
- not specified
- Dose descriptor:
- NOAEL
- Effect level:
- 1 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- haematology
- histopathology: non-neoplastic
- Remarks on result:
- other: The oral administration of 1 mg/kg bw over 10 months revealed no effects compared to controls.
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (nominal)
- System:
- haematopoietic
- Organ:
- kidney
- liver
- spleen
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Conclusions:
- The oral administration of 1 mg/kg bw over 10 months revealed no effects. With higher doses haematological and histopathological findings (liver, lung, spleen) were repoted.
- Executive summary:
After a subchronic/chronic oral administration of 500 mg/kg bw of zinc ethylphenyldithiocarbamate to rats for 1.5 months some cases of deaths occurred. A dosage of 100 mg/kg bw or 10 mg/kg bw changes in the haemogram, the prothrombin time,and the cytochrome oxidase were observed. Histopathological effects on the liver, lung and kidneys were detected. The oral administration of 1 mg/kg bw over 10 months revealed no effects.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Organ:
- blood
- kidney
- liver
- lungs
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
A subchronic/chronic study with limited reported methodology and results (original paper in Russian language, Yalkut, 1971) is available. Due to methodological deficiencies and limited reporting the study is not suitable for a classification and labelling.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.